Skip to main content

MINI REVIEW article

Front. Oncol.
Sec. Radiation Oncology
Volume 14 - 2024 | doi: 10.3389/fonc.2024.1453256
This article is part of the Research Topic Evolving Strategies in Radiation Therapy for Benign Intracranial Tumors: Current Techniques, Clinical Challenges, and Future Prospects View all articles

Mini Review A Mini Review of Plan Quality and Secondary Cancer Risk in CyberKnife M6 Radiosurgery for Benign Intracranial Tumors

Provisionally accepted
Pei-Ju Chao Pei-Ju Chao 1Tsair-Fwu LEE Tsair-Fwu LEE 2*
  • 1 Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan
  • 2 National Kaohsiung University of Science and Technology, Kaohsiung, Taiwan

The final, formatted version of the article will be published soon.

    With advancements in medical technology, stereotactic radiosurgery (SRS) has become an essential option for treating benign intracranial tumors. Due to its minimal side effects and high local control rate, SRS is widely applied. This paper evaluates the plan quality and secondary cancer risk (SCR) in patients with benign intracranial tumors treated with the CyberKnife M6 system. The CyberKnife M6 robotic radiosurgery system features both multileaf collimator (MLC) and IRIS variable aperture collimator systems, providing different treatment options. The study included 15 patients treated with the CyberKnife M6 system, examining the differences in plan quality and SCR between MLC and IRIS systems. Results showed that MLC and IRIS plans had equal PTV (planning target volume) coverage (98.57% vs. 98.75%). However, MLC plans demonstrated better dose falloff and conformity index (CI: 1.81 ± 0.26 vs. 1.92 ± 0.27, P = 0.025). SCR assessment indicated that MLC plans had lower cancer risk estimates, with IRIS plans having average LAR (lifetime attributable risk) and EAR (excess absolute risk) values approximately 25% higher for cancer induction and 15% higher for sarcoma induction compared to MLC plans. The study showed that increasing tumor volume increases SCR probability, but there was no significant difference between different plans in PTV and brainstem analyses.

    Keywords: Stereotactic radiosurgery (SRS), CyberKnife M6, Multileaf collimator (MLC), Iris Collimator, Secondary cancer risk (SCR), treatment planning

    Received: 22 Jun 2024; Accepted: 23 Jul 2024.

    Copyright: © 2024 Chao and LEE. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Tsair-Fwu LEE, National Kaohsiung University of Science and Technology, Kaohsiung, Taiwan

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.